H influenza b Antibody IgG
A common method for evaluating suspected antibody deficiency is to immunize the patient with an appropriately selected vaccine, such as Tetanus, and determine vaccine-specific antibody concentrations in a serum sample 3-4 weeks post-immunization compared to a pre-immunization sample.
The Haemophilus influenza type B capsular polysaccharide is used as a solid phase antigen in a sensitive microtiter EIA. The assay is calibrated against the standard from the Centre for biologics Evaluation and Research, US Food and Drug Administration: Lot 1983. The minimal protective level in non-vaccinated individuals is greater than or equal to 0.15 mcg/mL. The protective level expected in recently vaccinated individuals is greater than or equal to 1.0 mcg/mL. This test has been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
2-3 business days from receipt of specimen
|Specimen Type||Order Code||CPT Code||NY Approved||Volume||Assay Range||Special Instructions|
1 mL (min. 200 uL)
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
Smith TF J Resp Dis 1989;10: 12-29
Shapiro G. et al. Pediatrics 1991; 87: 311-316
Halsey, J. F. et al. J Allergy and Clin Immunol (abstr),1992;89:272
Siber G, et al Ped Infect. Dis. Journal 1989;8:S84-S91
Popa V, Kim K, Heiner D. Annals of Allergy 1993; 70:418 - 424.
Kilpatrick DC. Transfusion Medicine 2002; 121: 335-351.
Akira S et al. Nature Immunol 2002; 2: 675-680.